ECSP066752A - Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida - Google Patents
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamidaInfo
- Publication number
- ECSP066752A ECSP066752A EC2006006752A ECSP066752A ECSP066752A EC SP066752 A ECSP066752 A EC SP066752A EC 2006006752 A EC2006006752 A EC 2006006752A EC SP066752 A ECSP066752 A EC SP066752A EC SP066752 A ECSP066752 A EC SP066752A
- Authority
- EC
- Ecuador
- Prior art keywords
- salt
- methyl
- phenyl
- tartrate
- ilmetile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a las sales de adición de ácido de 4-[4-metil-1-piperazinilmetil]-N-[4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]fenil]-benzamida, que se seleccionan del grupo que consiste de una sal de tartrato, tal como una sal de (D)(-)tartrato o sal de (L)(+) tartrato, sal de clorhidrato, sal de citrato, sal de malato, sal de fumarato, sal de succinato, sal de benzoato, sal de bencensulfonato, sal de pamoato, sal de formiato, sal de malonato, sal de 1,5-naftalendisulfonato, sal de silicato, sal de ciclohexansulfamiato, sal de lactato, sal de mandelato, sal de glutarato acuosa, sal de adipato, sal de escuarato, sal de vanilato, sal de oxaloacetato, sal de ascorbato, y sal de sulfato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54181704P | 2004-02-04 | 2004-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066752A true ECSP066752A (es) | 2006-11-16 |
Family
ID=34837520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006752A ECSP066752A (es) | 2004-02-04 | 2006-08-03 | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida |
Country Status (22)
Country | Link |
---|---|
US (3) | US20080249104A1 (es) |
EP (1) | EP1713792B1 (es) |
JP (1) | JP4937760B2 (es) |
KR (2) | KR20120127525A (es) |
CN (1) | CN100558723C (es) |
AR (1) | AR047530A1 (es) |
AU (1) | AU2005211514B2 (es) |
BR (1) | BRPI0507464A (es) |
CA (1) | CA2553887C (es) |
EC (1) | ECSP066752A (es) |
IL (1) | IL177005A (es) |
MA (1) | MA28428B1 (es) |
MY (1) | MY144177A (es) |
NO (1) | NO20063942L (es) |
NZ (1) | NZ548714A (es) |
PE (1) | PE20051096A1 (es) |
PH (1) | PH12013500157A1 (es) |
RU (1) | RU2375355C2 (es) |
TN (1) | TNSN06243A1 (es) |
TW (1) | TWI347186B (es) |
WO (1) | WO2005075454A2 (es) |
ZA (1) | ZA200605972B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
EP2578580A1 (en) | 2005-11-25 | 2013-04-10 | Novartis AG | G, I and K crystal forms of imatinib mesylate |
KR100799821B1 (ko) * | 2007-02-05 | 2008-01-31 | 동화약품공업주식회사 | 신규한 이마티닙 캠실레이트 및 그의 제조방법 |
US7550591B2 (en) | 2007-05-02 | 2009-06-23 | Chemagis Ltd. | Imatinib production process |
WO2008136010A1 (en) * | 2007-05-07 | 2008-11-13 | Natco Pharma Limited | A process for the preparation of highly pure imatinib base |
WO2009036753A2 (de) * | 2007-09-20 | 2009-03-26 | Schebo Biotech Ag | Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie |
JP2010540465A (ja) | 2007-09-25 | 2010-12-24 | テバ ファーマシューティカル インダストリーズ リミティド | 安定なイマチニブ組成物 |
EP2062885A1 (en) * | 2007-11-21 | 2009-05-27 | Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. | Acid addition salts of imatinib and formulations comprising the same |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
US20100330130A1 (en) * | 2009-05-22 | 2010-12-30 | Actavis Group Ptc Ehf | Substantially pure imatinib or a pharmaceutically acceptable salt thereof |
HRP20171415T4 (hr) | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
WO2011036305A2 (en) | 2009-09-28 | 2011-03-31 | Medizinische Universität Wien | New use of pdgfrbeta inhibitors |
PL389357A1 (pl) | 2009-10-22 | 2011-04-26 | Tomasz Koźluk | Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania |
KR101138840B1 (ko) * | 2009-12-28 | 2012-05-10 | 주식회사 셀트리온화학연구소 | 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 |
US20130060030A1 (en) | 2010-03-15 | 2013-03-07 | Natco Pharma Limited | Process for the preparation of highly pure crystalline imatinib base |
EA024088B1 (ru) | 2010-06-18 | 2016-08-31 | КРКА, д.д., НОВО МЕСТО | α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ |
WO2012090221A1 (en) | 2010-12-29 | 2012-07-05 | Cadila Healthcare Limited | Novel salts of imatinib |
AU2013245011B2 (en) | 2012-04-04 | 2017-11-23 | Intervet International B.V. | Solid oral pharmaceutical compositions for isoxazoline compounds |
WO2014016848A2 (en) | 2012-07-24 | 2014-01-30 | Laurus Labs Private Limited | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
WO2015017728A1 (en) | 2013-07-31 | 2015-02-05 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
EP3407874B1 (en) | 2016-01-25 | 2024-05-22 | KRKA, d.d., Novo mesto | Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor |
CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (es) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
JP3691861B2 (ja) * | 1994-09-14 | 2005-09-07 | 株式会社東芝 | 光ディスク用光パルス幅制御装置 |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6448293B1 (en) * | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
US6479692B1 (en) * | 2001-05-02 | 2002-11-12 | Nobex Corporation | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
GB0202873D0 (en) * | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
ATE339197T1 (de) * | 2002-03-15 | 2006-10-15 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten |
GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
EP2578580A1 (en) * | 2005-11-25 | 2013-04-10 | Novartis AG | G, I and K crystal forms of imatinib mesylate |
-
2005
- 2005-02-02 AR ARP050100395A patent/AR047530A1/es not_active Application Discontinuation
- 2005-02-02 MY MYPI20050400A patent/MY144177A/en unknown
- 2005-02-02 PE PE2005000124A patent/PE20051096A1/es not_active Application Discontinuation
- 2005-02-03 TW TW094103446A patent/TWI347186B/zh not_active IP Right Cessation
- 2005-02-03 AU AU2005211514A patent/AU2005211514B2/en not_active Ceased
- 2005-02-03 BR BRPI0507464-9A patent/BRPI0507464A/pt not_active IP Right Cessation
- 2005-02-03 JP JP2006551802A patent/JP4937760B2/ja not_active Expired - Fee Related
- 2005-02-03 NZ NZ548714A patent/NZ548714A/xx not_active IP Right Cessation
- 2005-02-03 US US10/597,287 patent/US20080249104A1/en not_active Abandoned
- 2005-02-03 WO PCT/EP2005/001077 patent/WO2005075454A2/en active Application Filing
- 2005-02-03 RU RU2006131548/04A patent/RU2375355C2/ru not_active IP Right Cessation
- 2005-02-03 KR KR1020127025616A patent/KR20120127525A/ko not_active Application Discontinuation
- 2005-02-03 CN CNB2005800032177A patent/CN100558723C/zh not_active Expired - Fee Related
- 2005-02-03 CA CA2553887A patent/CA2553887C/en not_active Expired - Fee Related
- 2005-02-03 EP EP05707165.6A patent/EP1713792B1/en active Active
- 2005-02-03 KR KR1020067015707A patent/KR20060135735A/ko active Application Filing
-
2006
- 2006-07-19 ZA ZA200605972A patent/ZA200605972B/en unknown
- 2006-07-20 IL IL177005A patent/IL177005A/en unknown
- 2006-08-01 MA MA29225A patent/MA28428B1/fr unknown
- 2006-08-03 TN TNP2006000243A patent/TNSN06243A1/en unknown
- 2006-08-03 EC EC2006006752A patent/ECSP066752A/es unknown
- 2006-09-04 NO NO20063942A patent/NO20063942L/no not_active Application Discontinuation
-
2012
- 2012-02-08 US US13/368,811 patent/US8513256B2/en not_active Expired - Fee Related
-
2013
- 2013-01-22 PH PH12013500157A patent/PH12013500157A1/en unknown
- 2013-07-19 US US13/946,000 patent/US20140051853A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066752A (es) | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida | |
WO2005095379A3 (en) | Crystalline methanesulfonic acid addition salts of imatinib | |
PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
DE60118430D1 (de) | Behandlung gastrointestinaler stroma-tumoren | |
PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
NO20061420L (no) | 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og | |
MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
PE20070795A1 (es) | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa | |
EA200901514A1 (ru) | Новая сольватная и кристаллическая форма производных карбамоилциклогексана | |
AR053984A1 (es) | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas | |
AR076433A1 (es) | Sales inhibidoras de cdk | |
EA201270204A1 (ru) | Таблетка | |
NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
NO20064114L (no) | Fremgangsmate for fremstilling av N-arylpiperazinderivater | |
HK1087638A1 (en) | Use of tyrosine kinase inhibitors to treat diabetes | |
BR112023004656A2 (pt) | Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio | |
DE602005018171D1 (de) | Verfahren zur herstellung von ziprasidon | |
TH74677A (th) | รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด | |
NO20072501L (no) | Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS | |
TH74677B (th) | รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด | |
WO2004103374A3 (en) | Imatinib combinations for head and neck cancers | |
UY28498A1 (es) | Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso. | |
DE60305460D1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen | |
AR055284A1 (es) | R-enantiomeros de n- propargil- 1- aminoindano, sales, composiciones y usos de los mismos | |
ATE480534T1 (de) | Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz |